Non-Homologous DNA End Joining in Anticancer Therapy

Title: Non-Homologous DNA End Joining in Anticancer Therapy

Volume: 7 Issue: 3

Author(s): Elzbieta Pastwa and Mariusz Malinowski

Affiliation:

Keywords: Non-homologous DNA end joining, NHEJ, DNA double-strand breaks, DSBs, DNA-dependent protein kinase, DNA-PK, chemosensitization, radiosensitization

Abstract: Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Cite this article as:

Pastwa Elzbieta and Malinowski Mariusz, Non-Homologous DNA End Joining in Anticancer Therapy, Current Cancer Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/156800907780618284